G&G Biotechnology

Company Overview

Snapshot

Founded in April 2006 by Dael Govreen-Segal and Jacky Govrin-Yehudain, G&G Biotechnology operated with 1–10 employees. The company was acquired by POLYTECH Health & Aesthetics in July 2018, marking a significant exit in the medical technology sector.

Business overview

G&G Biotechnology developed a comprehensive product line of lightweight breast implants for augmentation and reconstruction, utilizing its patented B-Lite technology. These implants were designed to allow for larger volumes while mitigating risks associated with increased weight. The company operated within the Health Tech & Life Sciences sector, specifically focusing on medical devices and treatment therapeutics, serving the healthcare and biotechnology markets.

Strategic signal

In July 2018, G&G Biotechnology merged with POLYTECH Health & Aesthetics, becoming a subsidiary. This strategic move indicates a consolidation within the breast implant market, with POLYTECH integrating G&G Biotechnology's B-Lite technology to expand its product offerings and market reach in breast aesthetics.

Company Intelligence Q&A

What is G&G Biotechnology's primary product?

G&G Biotechnology developed B-Lite, the world's first lightweight breast implant technology, designed for both augmentation and reconstruction procedures.

When was G&G Biotechnology founded?

G&G Biotechnology was founded in April 2006.

Who are the founders of G&G Biotechnology?

The company was co-founded by Dael Govreen-Segal and Jacky Govrin-Yehudain.

What was a significant corporate milestone for G&G Biotechnology?

In July 2018, G&G Biotechnology merged with POLYTECH Health & Aesthetics, becoming a subsidiary of the company.

What market does G&G Biotechnology primarily serve?

G&G Biotechnology primarily serves the medical aesthetics market, specifically focusing on breast augmentation and reconstruction with its lightweight implant technology.